Share ownership Ocugen, Inc.

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2026 am IST			5-day change	1st Jan Change
1.390 ^USD	-4.79%		-7.95%	+2.96%

15/05	Ocugen Closes Offering of Senior Notes Due 2034	MT
06/05	Ocugen, Inc., Q1 2026 Earnings Call, May 05, 2026

Share class: Ocugen, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	33,86,43,356	33,28,23,345 ( 98.28 %)	1,21,500 ( 0.0359 %)	98.28 %

Major shareholders: Ocugen, Inc.

Name	Equities	%	Valuation
Millennium Management LLC 5.044 %	1,70,74,584	5.044 %	30 M $
Vanguard Capital Management LLC 4.078 %	1,38,04,111	4.078 %	24 M $
Millennium Management LLC 4.055 %	1,37,27,192	4.055 %	24 M $
STATE STREET CORPORATION 2.857 %	96,70,191	2.857 %	17 M $
Marshall Wace LLP 2.379 %	80,52,350	2.379 %	14 M $
UBS Financial Services, Inc. 2.139 %	72,41,072	2.139 %	13 M $
BlackRock Institutional Trust Co. NA 2.1 %	71,07,654	2.1 %	12 M $
RTW Investments LP 1.969 %	66,66,666	1.969 %	12 M $
Shankar Musunuri 1.802 %	61,01,223	1.802 %	11 M $
Geode Capital Management LLC 1.249 %	42,27,104	1.249 %	7 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	29.86%
Other	4.84%
State Street Corp.	2.86%
Individuals	2.71%
Baader Bank AG	0.01%
Governments	0.01%
Unknown	59.71%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	33.32%
Individuals	2.71%
United Kingdom	2.63%
France	1.11%
Canada	0.12%
Cayman Islands	0.1%
Hong Kong	0.08%
Japan	0.07%
Ireland	0.06%
Australia	0.05%
Switzerland	0.01%
Germany	0.01%
China	0.01%
Netherlands	0.01%

Based on 1000 largest holdings

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

Employees

116

Sector

Biotechnology & Medical Research

More about the company